Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 98 clinical trials
featured
A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy (SAPPHIRE)

docetaxel in patients with advanced non-squamous NSCLC who have previously experienced radiographic disease progression on or after treatment with platinum-based chemotherapy in combination with CIT.

cancer chemotherapy
non-squamous non-small cell lung cancer
lung carcinoma
nivolumab
advanced lung cancer
  • 229 views
  • 26 Aug, 2021
  • 199 locations
featured
  • 144 views
  • 25 Mar, 2021
  • 1 location
featured
Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

  • 140 views
  • 08 Nov, 2020
  • 1 location
featured
Advanced Colorectal or Lung Cancer Screening

Advanced Colorectal or Lung Cancer Screening

  • 158 views
  • 25 Mar, 2021
  • 1 location
KN046 in Subjects With Advanced Squamous Non-small Cell Lung Cancer

paclitaxel and carboplatin in subjects with advanced squamous NSCLC who have not previously received systemic treatment.

  • 0 views
  • 26 Jan, 2021
  • 1 location
SAR408701 in Combination With Ramucirumab in Pre-treated Patients With Non Squamous Non-small Cell Lung Cancer (NSQ NSCLC)

Primary Objectives: Part 1 (safety run-in): To assess the tolerability and to confirm the recommended dose of SAR408701 in combination with ramucirumab in the NSQ NSCLC population. Part 2: To assess the antitumor activity of SAR408701 in combination with ramucirumab in the NSQ NSCLC population. Secondary Objectives: To assess the …

cancer
platinum-based chemotherapy
squamous non-small cell lung cancer
measurable disease
  • 0 views
  • 02 Aug, 2021
  • 18 locations
A Randomized Double-blind Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC

advanced or metastatic squamous NSCLC who have not previously received systemic treatment. Eligible subjects in this study will be randomized to Arm A or Arm B at 2:1 ratio as follows: Arm A

  • 5 views
  • 03 Feb, 2021
  • 3 locations
A Study to Compare the Similarity in Efficacy and Safety Between TRS003 and China-approved Bevacizumab in NSCLC

with unresectable, locally advanced, or metastatic non-squamous non-small cell lung cancer (NSCLC). Approximately 608 patients will be enrolled in this study from America, Europe, and Asia. Patients

  • 0 views
  • 25 Jan, 2021
  • 10 locations
SAR408701 Versus Docetaxel in Previously Treated Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small Cell Lung Cancer Patients

(PFS) when compared to docetaxel in participants with metastatic non-squamous NSCLC expressing CEACAM5 2+ in intensity in at least 50% of the tumor cell population and previously treated with standard

measurable disease
cancer
platinum-based chemotherapy
docetaxel
squamous non-small cell lung cancer
  • 23 views
  • 19 Sep, 2021
  • 218 locations
KEYMAKER-U01 Substudy 1: Efficacy and Safety Study of Pembrolizumab (MK-3475) Plus Chemotherapy When Used With Investigational Agents in Treatment-na ve Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)

with advanced squamous or non-squamous NSCLC. This study is one of three pembrolizumab substudies being conducted under one pembrolizumab umbrella master protocol (MK-3475-U01/KEYMAKER-U01).

cancer chemotherapy
mk-3475
lung carcinoma
pemetrexed
targeted therapy
  • 2 views
  • 04 Sep, 2021
  • 28 locations